Search results

24 results

Sorted by Date . Sort by Relevance

  1. Maintaining immunisation programmes (PDF)

    Publications approval reference: 001559 Maintaining routine immunisation programmes during COVID-19 November 2020, updated June 2021 General...

  2. Clinical guide to surgical prioritisation

    (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0]

  3. ICON for midwives (PDF)

    Publications approval reference: 001559 NHS England and NHS Improvement Specialty guides for patient management during the coronavirus pandemic

  4. Management of anticoagulant services (PDF)

    Publications approval reference: 001559 Specialty guides for patient management during the coronavirus pandemic Clinical guide for the management

  5. Management of stroke patients (PDF)

    NHS England and NHS Improvement Publications approval reference: 001559 Specialty guides for patient management during the coronavirus pandemic

  6. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

    Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children

  7. Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

    Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherit

  8. Patisiran for treating hereditary transthyretin amyloidosis (HST10)

    Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

  9. Inotersen for treating hereditary transthyretin amyloidosis (HST9)

    Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis

  10. Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people